IN2012DN03032A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03032A
IN2012DN03032A IN3032DEN2012A IN2012DN03032A IN 2012DN03032 A IN2012DN03032 A IN 2012DN03032A IN 3032DEN2012 A IN3032DEN2012 A IN 3032DEN2012A IN 2012DN03032 A IN2012DN03032 A IN 2012DN03032A
Authority
IN
India
Prior art keywords
receptor antagonist
arb
salts
manufacture
processes
Prior art date
Application number
Other languages
English (en)
Inventor
Gottfried Sedelmeier
Florian Andreas Rampf
Dominique Grimler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41716392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03032(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2012DN03032A publication Critical patent/IN2012DN03032A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/32Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/32Separation; Purification; Stabilisation; Use of additives
    • C07C253/34Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/50Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IN3032DEN2012 2009-10-27 2010-10-25 IN2012DN03032A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09174264A EP2316821A1 (en) 2009-10-27 2009-10-27 Process for the manufacture of organic compounds
PCT/EP2010/066041 WO2011051213A1 (en) 2009-10-27 2010-10-25 Process for the manufacture of organic compounds

Publications (1)

Publication Number Publication Date
IN2012DN03032A true IN2012DN03032A (sl) 2015-07-31

Family

ID=41716392

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3032DEN2012 IN2012DN03032A (sl) 2009-10-27 2010-10-25

Country Status (23)

Country Link
US (1) US20120238761A1 (sl)
EP (2) EP2316821A1 (sl)
JP (1) JP2013508436A (sl)
KR (1) KR20120098652A (sl)
CN (1) CN102596899A (sl)
AR (1) AR079104A1 (sl)
AU (1) AU2010311636B2 (sl)
BR (1) BR112012009815A2 (sl)
CA (1) CA2777031A1 (sl)
CL (1) CL2012001081A1 (sl)
CO (1) CO6531487A2 (sl)
EC (1) ECSP12011833A (sl)
IL (1) IL219111A0 (sl)
IN (1) IN2012DN03032A (sl)
MA (1) MA33692B1 (sl)
MX (1) MX2012005025A (sl)
NZ (1) NZ599218A (sl)
PE (1) PE20121501A1 (sl)
RU (1) RU2012121591A (sl)
TN (1) TN2012000154A1 (sl)
TW (1) TW201124389A (sl)
WO (1) WO2011051213A1 (sl)
ZA (1) ZA201202490B (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102321038B (zh) * 2011-07-11 2014-03-26 安徽省虹升生物科技有限公司 一种改进的制备缬沙坦方法
FR2981077B1 (fr) * 2011-10-11 2013-11-01 Michelin Soc Tech Methode pour preparer un melange maitre d'elastomere dienique et de silice
WO2018040065A1 (zh) * 2016-09-02 2018-03-08 诺瑞特国际药业股份有限公司 缬沙坦二钠盐的晶型
CN110078640B (zh) * 2019-03-29 2022-04-05 浙江美诺华药物化学有限公司 一种缬沙坦中间体的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874867A (en) 1987-05-22 1989-10-17 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
IL97219A (en) * 1990-02-19 1995-12-08 Ciba Geigy Ag Elliptical amino compounds converted by biphenyl process for their preparation and pharmaceutical preparations containing them
JPH04297466A (ja) 1990-06-22 1992-10-21 Nippon Shinyaku Co Ltd テトラゾール誘導体及び医薬
GB9222700D0 (en) * 1992-10-29 1992-12-09 Smithkline Beecham Plc Chemical compounds
GB0222056D0 (en) 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
ITMI20032267A1 (it) 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
HRP20030965A2 (en) * 2003-11-24 2005-08-31 Belupo - Lijekovi I Kozmetika D.D. Process for production of (s)-n-pentanoyl-n-[[2'-(
US20060281801A1 (en) * 2005-04-19 2006-12-14 Ashok Kumar Process for the preparation of valsartan and its intermediates
JP2009504800A (ja) * 2005-08-22 2009-02-05 アレンビク リミテッド バルサルタンの調製方法
US7880015B2 (en) * 2006-07-03 2011-02-01 Aurobindo Pharma Ltd. Process for the preparation of angiotensin II antagonist
CN101450917B (zh) * 2007-12-06 2012-07-11 浙江海正药业股份有限公司 缬沙坦的合成方法
US7943794B2 (en) * 2008-02-13 2011-05-17 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan

Also Published As

Publication number Publication date
BR112012009815A2 (pt) 2016-10-18
US20120238761A1 (en) 2012-09-20
EP2493848A1 (en) 2012-09-05
AU2010311636B2 (en) 2014-03-06
TW201124389A (en) 2011-07-16
TN2012000154A1 (en) 2013-12-12
KR20120098652A (ko) 2012-09-05
JP2013508436A (ja) 2013-03-07
AU2010311636A1 (en) 2012-05-03
CL2012001081A1 (es) 2013-06-14
MX2012005025A (es) 2012-06-08
CN102596899A (zh) 2012-07-18
EP2316821A1 (en) 2011-05-04
CO6531487A2 (es) 2012-09-28
NZ599218A (en) 2014-02-28
MA33692B1 (fr) 2012-10-01
IL219111A0 (en) 2012-06-28
ECSP12011833A (es) 2012-06-29
WO2011051213A1 (en) 2011-05-05
PE20121501A1 (es) 2012-11-15
CA2777031A1 (en) 2011-05-05
ZA201202490B (en) 2012-12-27
AR079104A1 (es) 2011-12-28
RU2012121591A (ru) 2013-12-10

Similar Documents

Publication Publication Date Title
TN2011000673A1 (en) Bace inhibitors
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
UA115136C2 (uk) Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1
IN2012DN02642A (sl)
WO2011022596A3 (en) Preparation of bazedoxifene and its salts
CL2009000503A1 (es) Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida.
WO2013098833A3 (en) Processes and intermediates for preparing rivaroxaban
IN2014CN04160A (sl)
MX2010009003A (es) Ciclohexanodimetanamina por aminacion directa de ciclohexanodimetanol.
UA105785C2 (uk) Спосіб очищення ліпопептидів
GEP20135903B (en) Method of (1s, 2r)-milnacipran synthesis
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
MX2010000724A (es) Metodo para reducir presion intracraneal.
WO2012015999A3 (en) Process for the preparation of imatinib mesylate
UA106619C2 (uk) Спосіб отримання похідних 1-(2-галогенбіфеніл-4-іл)-циклопропанкарбонової кислоти
IN2012DN03032A (sl)
WO2012017448A3 (en) Salts of lapatinib
UA106386C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
MX2012006524A (es) Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindol.
IN2012DN01929A (sl)
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
WO2012063115A3 (en) Process for the preparation of rosuvastatin calcium via novel amine intermediate
IN2014DN10209A (sl)
UA110626C2 (uk) Спосіб одержання пан-інгібіторів циклінзалежної кінази формули (i), а також проміжні продукти цього процесу одержання
MY183201A (en) Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds